Feature|Articles|March 13, 2024
- Pharmaceutical Executive: March 2024
- Volume 44
- Issue 3
Pharmaceutical Executive: March 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
How’s Business?over 2 years ago
Eyeing Efficiency for Allover 2 years ago
Positioning Medical Information as a Trust Driver for Your Brandover 2 years ago
Straight and Simple Advice Lives On in the Pharma Industryover 2 years ago
A Return to the Fundamentals in Biotech Investment?over 2 years ago
The Shifting Landscape of the Life Sciences Job Marketover 2 years ago
Copay Adjustment Programs: What’s Next for Manufacturers?Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5